share_log

Anika Announces Steve Griffin Appointed To CFO, Effective June 3, 2024

Anika Announces Steve Griffin Appointed To CFO, Effective June 3, 2024

Anika 宣佈任命史蒂夫·格里芬爲首席財務官,自 2024 年 6 月 3 日起生效
Benzinga ·  05/08 17:56

Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, today announced that it has appointed Steve Griffin as the Company's Executive Vice President, Chief Financial Officer ("CFO") and Treasurer, effective June 3, 2024. He succeeds Michael Levitz, who has decided to step down as CFO after almost four years with the company. Mr. Levitz will remain with the Company through December 31, 2024, to ensure a smooth transition.

早期干預骨科領域的全球關節保護公司Anika Therapeutics, Inc.(納斯達克股票代碼:ANIK)今天宣佈,已任命史蒂夫·格里芬爲公司的執行副總裁、首席財務官(“首席財務官”)兼財務主管,自2024年6月3日起生效。他接替了邁克爾·萊維茨,後者在公司工作了將近四年後決定辭去首席財務官的職務。萊維茨先生將在公司任職至2024年12月31日,以確保平穩過渡。

"We are pleased to welcome Steve to Anika as we focus on accelerating our pivot to profitability," said Cheryl Blanchard, Ph.D., Anika's President and CEO. "Steve is an accomplished public company leader whose ability to connect strategic, operational, and financial expertise will be a significant asset for our Company. I am confident that Steve will build on our recent momentum and partner with our operating teams to achieve the meaningful value building potential across the business."

阿尼卡總裁兼首席執行官謝麗爾·布蘭查德博士表示:“我們很高興歡迎史蒂夫加入阿尼卡,因爲我們專注於加快向盈利的轉變。”“史蒂夫是一位成就卓著的上市公司領導者,他整合戰略、運營和財務專業知識的能力將是我們公司的重要資產。我相信,Steve將在我們最近的勢頭基礎上再接再厲,與我們的運營團隊合作,在整個業務中實現有意義的價值創造潛力。”

Dr. Blanchard continued, "On behalf of the Anika team, I'd like to thank Mike for his leadership over the past four years. Mike joined Anika in mid-2020 following our two acquisitions. His strategic and operational insights have helped Anika navigate this period of significant change while positioning the Company for an exciting future driven by thoughtful investments in Anika's market-leading hyaluronic acid business and key product developments in the highest opportunity spaces of orthopedics. We are glad to continue benefitting from his expertise through the end of this year and wish him the best."

布蘭查德博士繼續說:“我謹代表阿尼卡團隊感謝邁克在過去四年中所發揮的領導作用。在我們進行了兩次收購之後,邁克於2020年中期加入了阿尼卡。他的戰略和運營見解幫助Anika度過了這段重大變革時期,同時在對Anika市場領先的透明質酸業務的深思熟慮的投資以及骨科機會最大的領域關鍵產品開發的深思熟慮的投資推動下,爲公司邁向了令人興奮的未來做好了準備。我們很高興在今年年底之前繼續受益於他的專業知識,並祝他一切順利。”

"Joining Anika represents an exciting opportunity to contribute to a well-established, market-leading organization with a strong track record of developing innovative solutions in the highest opportunity spaces in orthopedics," said Mr. Griffin. "I look forward to partnering with Cheryl and the talented Anika team to unlock new opportunities with its significant pipeline of differentiated product lines to deliver sustainable, profitable growth."

格里芬說:“加入Anika是一個激動人心的機會,可以爲一個成熟的、市場領先的組織做出貢獻,該組織在骨科機會最大的領域開發創新解決方案方面有着良好的記錄。”“我期待與Cheryl和才華橫溢的Anika團隊合作,通過其龐大的差異化產品線開啓新的機遇,實現可持續的盈利增長。”

"I'm very thankful for the opportunity to have been a part of the Anika team," said Mr. Levitz. "The Company has navigated a challenging period and made meaningful strides, including thoughtful investments as well as targeted cost reductions that together have strengthened its core OA business, advanced a meaningful portfolio and pipeline of differentiated products leveraging Anika's HA expertise, and maintained a healthy financial position. I am confident this progress will continue with Steve guiding our talented team and look forward to following Anika's success for years to come."

萊維茨說:“我非常感謝有機會加入阿尼卡團隊。”“公司度過了一個充滿挑戰的時期,取得了有意義的進展,包括周到的投資和有針對性的成本降低,這些措施共同加強了其核心OA業務,利用Anika的HA專業知識推進了有意義的產品組合和差異化產品管道,並保持了良好的財務狀況。我相信,在史蒂夫指導我們才華橫溢的團隊下,這一進展將繼續下去,並期待在未來幾年關注阿妮卡的成功。”

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論